期刊
STEM CELL REPORTS
卷 10, 期 3, 页码 933-941出版社
CELL PRESS
DOI: 10.1016/j.stemcr.2018.01.029
关键词
-
资金
- Major International (Regional) Joint Research Project [81720108020]
- National Natural Science Foundation of China [91442119, 81401347]
- Jiangsu Province Major Research and Development Program [BE2015602]
- Jiangsu Province 333 Talent grant [BRA2016001]
- National Key Research and Development Program of China [2017YFC0909003]
- Jiangsu Province Six Talent Project [WSN-156]
- Nanjing Outstanding Youth Foundation [JQX17004]
Allogeneic mesenchymal stem/stromal cells (MSCs) have been widely studied as an alternative cell source for regenerative medicine. Here, we report a long-term follow-up study of allogeneic bone marrow and/or umbilical cord MSC transplantation (MSCT) in severe and drug-refractory systemic lupus erythematosus (SLE) patients. Eighty-one patients were enrolled, and the 5-year overall survival rate was 84% (68/81) after MSCT. At 5-year follow-up, 27% of patients (22/81) were in complete clinical remission and another 7% (6/81) were in partial clinical remission, with a 5-year disease remission rate of 34% (28/81). In total, 37 patients had achieved clinical remission and then 9 patients subsequently relapsed, with 5-year overall rate of relapse of 24% (9/37). SLE Disease Activity Index scores, serum albumin, complement C3, peripheral white blood cell, and platelet numbers, as well as proteinuria levels, continued to improve during the follow-up. Our results demonstrated that allogeneic MSCT is safe and resulted in long-term clinical remission in SLE patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据